Monoclonal antibodies for the treatment of COVID-19 infection in children.

Introduction: Monoclonal antibodies (mAbs) have been authorized for the treatment of COVID-19 in pediatric populations, however, there is a lack of evidence for their use in these populations.

Areas Covered: We outline the evidence of mAbs for COVID-19, discuss their use in the treatment of COVID-19 infection for pediatric patients, and consider alternative treatment options and challenges to COVID-19 drug approvals.

Expert Opinion: Limited evidence exists for the safety and efficacy of mAbs to treat COVID-19 in children as new variants emerge.